Table 1.
Post neoadjuvant endocrine therapy residual disease factors comprising the PEPI score* for RFS and BCSS
| Factor | RFS risk points | BCSS risk points |
|---|---|---|
| Pathologic T stage | ||
| pT0–2 | 0 | 0 |
| pT3/4 | 3 | 3 |
| Pathologic N stage | ||
| pN0 | 0 | 0 |
| pN1–3 | 3 | 3 |
| ER Allred score | ||
| 0–2 | 3 | 3 |
| 3–8 | 0 | 0 |
| Ki67 level | ||
| 0–2.7% | 0 | 0 |
| 2.8–7.3% | 1 | 1 |
| 7.4–19.7% | 1 | 2 |
| 19.8–53.1% | 2 | 3 |
| 53.2% or more | 3 | 3 |
*
Determining PEPI score: a patient’s PEPI score is determined by summing risk points corresponding to pT stage, pN stage, Ki67 and Allred score from their surgical specimen disease following neo-adjuvant endocrine therapy. For example, a patient with a pT2 pN1 tumor with Ki67 =5% and ER Allred score =5 would be assigned a PEPI score of 4 (0+3+1+0) for both RFS and BCSS. RFS, relapse-free survival; BCSS, breast cancer specific survival.